Heart failure evidence update 2026
Heart Failure Reviews · 2026 · Europe
Source and licence
- Authors
- Sotiria Liori, Chris J Kapelios, Gianluigi Savarese et al.
- Title
- Heart failure evidence update 2026
- Journal
- Heart Failure Reviews, 2026
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC12979370
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
This is a review of another guideline (ESC heart failure guidelines (2021, 2023 focused update) and newer evidence, ESC/HFA 2026). We do not reproduce that guideline's recommendations here – they belong to the original guideline.
Open the original publication →Full text on Europe PMC
Abstract
The interval since the 2021 European Society of Cardiology (ESC) Guidelines and 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) Guidelines publications has witnessed an unprecedented volume of evidence that substantially expands the therapeutic landscape across the entire ejection fraction (EF) spectrum. Major developments include the emergence of non-steroidal mineralocorticoid receptor antagonists and incretin-based therapies for heart failure (HF) with mildly reduced and preserved EF, the validation of rapid guideline-directed medical therapy optimization strategies in acute HF, and new evidence supporting digitalis glycosides in HF patients with reduced EF. Device-based care has evolved with transcatheter edge-to-edge repair for valvular heart disease. These data are likely to reshape contemporary clinical practice.
Contents of the original publication
The section headings of the original.
- Introduction
- Acute heart failure: rapid optimization and decongestion strategies
- SGLT2i: therapy across the ejection fraction spectrum
- Non-steroidal mineralocorticoid receptor antagonists
- Incretin-based therapies: targeting the obesity-heart failure phenotype
- Digitalis glycosides: new evidence in contemporary practice
- Additional pharmacologic agents in heart failure with reduced ejection fraction
- Intravenous iron therapy: refining patient selection
- Real-world implementation of guideline-directed medical therapy
- Remote hemodynamic monitoring: pulmonary artery pressure-guided management
- Transcatheter edge-to-edge repair: from mitral to tricuspid valve
- Interatrial shunt devices
- Conclusion
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint